Related Experiment Video
Updated: May 2, 2026
Functional Cloning Using a Xenopus Oocyte Expression System
Published on: January 30, 2016
Engineering Xenopus embryos for phenotypic drug discovery screening
Stefan M Schmitt1, Mazhar Gull1, André W Brändli1
1Walter Brendel Center of Experimental Medicine, Ludwig-Maximilians-University Munich, Munich, Germany.
Abstract:
Many rare human inherited diseases remain untreatable despite the fact that the disease causing genes are known and adequate mouse disease models have been developed. In vivo phenotypic drug screening relies on isolating drug candidates by their ability to produce a desired therapeutic phenotype in whole organisms. Embryos of zebrafish and Xenopus frogs are abundant, small and free-living. They can be easily arrayed in multi-well dishes and treated with small organic molecules. With the development of novel genome modification tools, such a zinc-finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), and CRISPR/Cas, it is now possible to efficiently engineer non-mammalian models of inherited human diseases. Here, we will review the rapid progress made in adapting these novel genome editing tools to Xenopus. The advantages of Xenopus embryos as in vivo models to study human inherited diseases will be presented and their utility for drug discovery screening will be discussed. Being a tetrapod, Xenopus complements zebrafish as an indispensable non-mammalian animal model for the study of human disease pathologies and the discovery of novel therapeutics for inherited diseases.
Insights
Xenopus embryos, engineered with genome editing tools like CRISPR/Cas, offer a powerful new model for studying rare inherited diseases and screening for effective drug treatments.
Area of Science:
- Developmental Biology
- Genetics
- Pharmacology
Background:
- Many rare human inherited diseases lack effective treatments, even when causative genes and animal models are known.
- In vivo phenotypic drug screening requires models that allow for efficient testing of drug candidates.
- Non-mammalian models are valuable for studying human diseases and discovering therapeutics.
Purpose of the Study:
- To review the application of genome editing tools in Xenopus for modeling human inherited diseases.
- To discuss the advantages of Xenopus embryos as in vivo models for disease research.
- To explore the utility of Xenopus embryos in drug discovery screening.
Main Methods:
- Utilizing novel genome editing tools such as zinc-finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), and CRISPR/Cas.
- Engineering Xenopus embryos to create models of human inherited diseases.
- Employing Xenopus embryos in high-throughput in vivo phenotypic drug screening.
Main Results:
- Rapid progress has been made in adapting genome editing tools to Xenopus.
- Xenopus embryos are suitable for in vivo phenotypic drug screening due to their abundance, small size, and ease of manipulation.
- Engineered Xenopus models can effectively study human inherited disease pathologies.
Conclusions:
- Xenopus embryos represent a valuable and complementary non-mammalian model to zebrafish for investigating human inherited diseases.
- Genome-edited Xenopus embryos are highly effective for in vivo drug discovery and the identification of novel therapeutics for untreatable genetic disorders.
